Table 3 Total and drug-related serious adverse events, hospitalizations, and discontinuations
From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
| Â | Total AEs | Drug-related AEs | ||||
|---|---|---|---|---|---|---|
Subgroup | SAEs | Hosp | D/C | SAEs | Hosp | D/C |
Anemia, n (%) | ||||||
 PTCL | 2 (2) | 2 (2) | 0 | 2 (2) | 2 (2) | 0 |
 CTCL | 1 (1) | 1 (1) | 0 | 1 (1) | 1 (1) | 0 |
Neutropenia, n (%) | Â | Â | Â | Â | Â | Â |
 PTCL | 7 (5) | 7 (5) | 2 (2) | 5 (4) | 5 (4) | 2 (2) |
 CTCL | 2 (2) | 0 | 1 (1) | 2 (2) | 0 | 1 (1) |
Thrombocytopenia, n (%) | ||||||
 PTCL | 2 (2) | 1 (1) | 3 (2) | 1 (1) | 1 (1) | 3 (2) |
 CTCL | 0 | 0 | 1 (1) | 0 | 0 | 1 (1) |
Nausea and vomiting, n (%) | ||||||
 PTCL | 6 (5) | 6 (5) | 0 | 4 (3) | 4 (3) | 0 |
 CTCL | 0 | 0 | 0 | 0 | 0 | 0 |
Asthenic conditions, n (%) | ||||||
 PTCL | 2 (2) | 2 (2) | 2 (2) | 0 | 0 | 1 (1) |
 CTCL | 2 (2) | 1 (1) | 4 (4) | 1 (1) | 1 (1) | 4 (4) |
Infections, n (%) | ||||||
 PTCL | 25 (19) | 21 (16) | 6 (5) | 6 (5) | 3 (2) | 2 (2) |
 CTCL | 8 (8) | 8 (8) | 5 (5) | 5 (5) | 5 (5) | 3 (3) |